Nan Fung Group Holdings Ltd Has $5.18 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Nan Fung Group Holdings Ltd grew its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 18.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 125,330 shares of the company's stock after acquiring an additional 19,230 shares during the quarter. Mirum Pharmaceuticals comprises approximately 4.4% of Nan Fung Group Holdings Ltd's portfolio, making the stock its 6th biggest holding. Nan Fung Group Holdings Ltd owned approximately 0.26% of Mirum Pharmaceuticals worth $5,182,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Barclays PLC raised its holdings in Mirum Pharmaceuticals by 4.6% in the 3rd quarter. Barclays PLC now owns 245,918 shares of the company's stock valued at $9,592,000 after acquiring an additional 10,824 shares during the last quarter. Geode Capital Management LLC grew its holdings in Mirum Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company's stock valued at $36,519,000 after buying an additional 29,017 shares during the period. Lord Abbett & CO. LLC acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter worth approximately $28,913,000. Hennion & Walsh Asset Management Inc. increased its position in Mirum Pharmaceuticals by 25.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company's stock worth $6,021,000 after purchasing an additional 29,545 shares during the last quarter. Finally, Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at $189,000.

Mirum Pharmaceuticals Stock Up 1.8 %

Shares of MIRM stock traded up $0.71 during trading hours on Thursday, hitting $40.33. 106,566 shares of the company were exchanged, compared to its average volume of 522,460. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of -20.04 and a beta of 1.00. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $54.23. The business's 50-day simple moving average is $44.55 and its two-hundred day simple moving average is $43.94.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The firm had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MIRM has been the subject of a number of research reports. HC Wainwright boosted their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $58.20.

Insider Activity at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 902 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $43,223.84. Following the completion of the transaction, the senior vice president now owns 3,524 shares of the company's stock, valued at approximately $168,870.08. The trade was a 20.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Peetz sold 27,279 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. This trade represents a 16.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 116,473 shares of company stock valued at $5,249,134 in the last quarter. Insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.